Baxter paying $18M to settle federal case over sterile plant failings

Justice statue with sword and scales
Baxter International has admitted selling adulterated sterile products and agreed to pay more than $18 million in penalties.

Ignoring issues in a sterile manufacturing plant can lead to big problems, like FDA warning letters, which Baxter International received for a plant in North Carolina after mold was found in HEPA filters. But in rare cases, it can lead to even more severe penalties, like the $18 million-plus Baxter will pay to resolve a federal criminal case, as well as a civil matter brought by a whistleblower over the mold concerns.  

The Justice Department Thursday announced the deal, saying the Deerfield, IL company admitted that it distributed “adulterated” products and will pay $16 million in penalties and forfeiture as part of a deferred prosecution agreement. It also agreed to regularly report about improvements made to its manufacturing operations.

Baxter will pay another $2.158 million to resolve a civil whistleblower case brought by Baxter employee Christopher Wall who had reported to the mold problem to plant management. Wall's case alleged his concerns were overlooked and the plant continued to manufacture and sell product from the facility. An FDA inspection in 2012 that led to a warning letter. Wall gets $431,535.99 as his share of the settlement.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

The DOJ said there was no evidence that the mold affected the IV solutions made at the facility during the 2011 and 2012 time period in question.

Baxter in a statement said, “We took a number of actions to address these issues, including terminating several members of the facility’s management team and enhancing the training and compliance processes for employees throughout the facility. We also undertook a number of actions to remediate the line and ensure continued compliance with quality standards, including physical changes to the line and implementing enhanced measures for inspections and environmental monitoring. And we’ve made a number of organizational and operational changes since 2012 that have served to elevate and enhance our quality systems, measurement and documentation, and operational oversight, in order to ensure we have the structure and processes in place to consistently deliver the high quality products our patients need and our customers expect.”

The company also said that its “extensive monitoring systems” had not uncovered an increases in complaints or patient adverse events for the products made on the lines during this time period.

That said, mold has shown up in Baxter products that made it to the market. In 2014, the company recalled one lot of a peritoneal product used on dialysis patients that was contaminated with mold. There were customer complaints about the product and the FDA reported there were reported adverse events. Baxter at the time said no causal relationship between the mold and the reported events had been established.

The DOJ said the case represents the kind of penalties companies can face for failing to meet FDA manufacturing standards.

“Despite notification by an employee of potential contamination concerns, Baxter was poorly focused on instituting sufficient safety standards for their products,” U.S. Attorney Jill Westmoreland Rose of the Western District of North Carolina said in a statement. “Today’s resolution reflects WDNC’s commitment to hold accountable drug companies that violate manufacturing standards and wrongly profit from those violations.”

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.